



**EUROPEAN UNION OF MEDICAL SPECIALISTS (UEMS)**  
**EUROPEAN ACCREDITATION COUNCIL FOR CME (EACCME®)**

RUE DE L'INDUSTRIE 24, BE- 1040 BRUSSELS  
T + 32 2 649 51 64  
[eaccme.uems.eu](http://eaccme.uems.eu) - [elarning@uems.eu](mailto:elarning@uems.eu)

## **Conflict of Interest Disclosure Form**

(to be completed by the individual(s) involved in the preparation of the ELM)

NAME **Cristina Saura Manich MD,PhD**

AFFILIATION: Head, Breast Cancer Unit. Medical Oncology Service. Vall d'Hebron University Hospital. (VHIO)

In accordance with criterion 18 of document UEMS 2023/08 "EACCME® Criteria for the Accreditation of E-Learning Materials (ELM)", all declarations of perceived or actual conflicts of interest for the last 3 years, whether due to a financial or other relationship, must be provided to the EACCME® upon submission of the application. Declarations must be made available online on the ELM page. Declarations must include whether any fee, honorarium or arrangement for re-imburement of expenses in relation to the ELM has been provided.

### **DISCLOSURE**

- I have no potential conflict of interest to report
- I have the following potential conflict(s) of interest to report

#### **Type of affiliation / financial interest**

#### **Name of commercial company**

Receipt of grants/research supports:

AX'Consulting,AX's Consulting  
SARL,AstraZeneca,Boehringer  
Ingelheim,Bristol Meyers Squibb,Byondis  
BV,Daiichi Sankyo,Eisai,Exeter Pharma,F.  
Hoffmann - La Roche Ltda,Genentech,Grupo  
de  
mama,alemán,Galaad,Glaxo,INDITEX,ISSECA  
M,Innoup,Grupo Internacional de Estudio  
del Cáncer de Mama  
(IBCSG,)Iriomacrogénicos,MediTech,Consult  
oría deEstadísticas  
Médicas,Medseñor,Menarini,Merck Sharp &  
Döhme,Merus,Milenio,Instituto Holandés  
del Cáncer (NKI),Novartis,Pfizer,Philips,Piere  
Fabre,Pintafarma,Puma,Queen Mary  
(Universidad de Londres),RocheFarma,SACE  
Medhealth SL,Sanofi,Sanofi  
Aventis,Seagen,Genética de Seattle,Simon  
Kucher & Partners SL,Solti,Biofarmacéuticos  
Synthon,Zymeworks

Receipt of honoraria or consultation fees:

AstraZéneca,Daiichi Sankyo,Eisai Europe,Ltd.,Gilead,Novartis,Pharmalex,Pfizer Inc,Phillips Health Works,Pierre Fabre,PintPharma,Puma Biotechnology Inc,Roche Farma, SA,Seagen Int., Solti,Synthon Biopharmaceuticals,Zymeworks, Lilly SAU, MediTech,Pierre Fabré,

Participation in a company sponsored speaker's bureau:

AX's Consulting SARL, Boehringer Ingelheim, Bristol Meyers Squibb, Genentech, Inditex, Innoup, Merck Sharp & Dohme España, Millenium, Novartis, SACE , Medhealth SL, Sanofi, Seattle Genetics, Simon Kucher &Partners SL, Daiichi Sankyo.

Stock shareholder: N/A

Spouse/partner: N/A

Other support (please specify):

**Company:** Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd'

**Signature:**

**Date:**